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Abstract
Background: Two of the most prevalent causes of severe bacterial meningitis in children, Haemophilus influenzae
type B (Hib) and Streptococcus pneumoniae, are preventable by existing vaccines increasingly available in
developing countries. Our objective was to estimate the dose-specific effect of Hib and pneumococcal conjugate
vaccines (PCV) on childhood meningitis mortality in low-income countries for use in the Lives Saved Tool (LiST).
Methods: We systematically searched and reviewed published vaccine efficacy trials and observational studies
reporting the effect of Hib or PCV vaccines on organism-specific meningitis, bacterial meningitis and all-cause
meningitis incidence and mortality among children less than five years old in low- and middle-income countries.
Data collection and quality assessments were performed using standardized guidelines. For outcomes available
across multiple studies (≥2) and approximating meningitis mortality, we pooled estimates reporting dose-specific
effects using random effects meta-analytic methods, then combined these with meningitis etiology data to
determine the preventable fraction of childhood meningitis mortality for inclusion in LiST.
Results: We identified 18 studies of Hib conjugate vaccines reporting relevant meningitis morbidity and mortality
outcomes (2 randomized controlled trials [RCTs], 16 observational studies) but few provided dose-specific effects.
A meta-analysis of four case-control studies examined the dose-specific effect of Hib conjugate vaccines on Hib
meningitis morbidity (1 dose: RR=0.64, 95% CI 0.38-1.06; 2 doses: RR=0.09, 95% CI 0.03-0.27; 3 doses: RR=0.06, 95% CI
0.02-0.22), consistent with results from single RCTs. Pooled estimates of two RCTs provided evidence for the effect of
three doses of PCV on vaccine-serotype meningitis morbidity (RR=0.16, 95% CI 0.02-1.20). We considered these
outcomes of severe disease as proxy estimates for meningitis mortality and combined the estimates of protective
effects with meningitis etiology data to provide an estimate of the preventable fraction of childhood meningitis
mortality with three doses of Hib (38-43%) and pneumococcal conjugate vaccines (28-35%) for use in LiST.
Conclusions: Few RCTs or vaccine effectiveness studies evaluated the dose-specific impact of Hib and PCV vaccines on
childhood meningitis mortality, necessitating use of proxy measures to estimate population impact in LiST. Our analysis
indicates that approximately three-quarters of meningitis deaths are preventable with existing Hib and PCV vaccines.
Background
Meningitis accounts for an estimated 180,000 deaths every
year in children less than five years of age globally; and
approximately 20% of survivors experience long-term dis-
abling sequelae [1,2]. Bacterial pathogens are responsible
for the majority of severe pediatric meningitis outside the
neonatal period, and many cases are preventable with
existing conjugate vaccines protective against Haemophi-
lus influenzae type B (Hib) and Streptococcus pneumoniae
(pneumococcus) forms of meningitis [3,4].
Although Hib and pneumococcal vaccines have been
available for more than a decade in developed countries,
they have only recently been made available to children in
low-income countries through financial support from the
GAVI Alliance. As of December 2012, nearly all low-
income GAVI-eligible countries (70/73) now have Hib
conjugate vaccine included in their national immunization
programs. The first GAVI-eligible country introduced
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pneumococcal conjugate vaccine (PCV) in 2009. Since
2009, 23 other countries have introduced PCV and 26
have approval for GAVI-supported PCV introductions
over the next 2 years [5,6].
Understanding the effectiveness of Hib and PCV vac-
cines remains critical to inform decision-making for the
remaining low- and middle-income countries yet to
introduce these vaccines into their national immuniza-
tion programs. Use of the existing evidence on the effec-
tiveness of Hib and PCV vaccines can also inform input
parameters for mathematical models such as the Lives
Saved Tool (LiST) [7], developed by the Child Health
Epidemiology Research Group (CHERG), to project the
number of lives saved by scaling up use of these vac-
cines in the context of other child survival interventions,
providing important information for program planning.
In the absence of an existing estimate for meningitis
mortality, LiST currently uses estimates of the effective-
ness of Hib and PCV against childhood pneumonia
morbidity as a proxy. Here we present a systematic
review and meta-analysis on the effects of Hib and PCV
vaccines in prevention of childhood meningitis mortal-
ity, with the intent to update parameters used in LiST
to model the dose-specific effectiveness of these vaccines
using consistent and standard methods according to
CHERG guidelines [8].
Methods
Study identification, selection and abstraction
We conducted a systematic search of the published
literature to identify both trials and observational studies
reporting on the effect of Hib or PCV vaccines on menin-
gitis-related morbidity and mortality outcomes among
children less than five years old in low- and middle-
income countries [9] published between 1990 and
December 2010. Search terms included various combina-
tions of terms for pneumococcal vaccine, Haemophilus
vaccine, and meningitis and used controlled vocabulary
where possible (Figure 1). Databases searched include
Pubmed, Embase, Web of Science, Scopus, Africa-Wide
Information, Global Health, Cochrane, and the WHO
Library database (WHOLIS) and WHO regional data-
bases (Index Medicus for the Eastern Mediterranean
Region, Western Pacific Region Index Medicus, African
Index Medicus, IndMed, PAHO Virtual Health Library,
and Latin America and Caribbean Health Sciences Litera-
ture (LILACS). We also searched the System for Informa-
tion on Grey Literature in Europe (SIGLE) and websites
including http://ClinicalTrials.gov, Hibaction, PneumoA-
DIP, and the World Health Organization Hib and Pneu-
mococcus for relevant citations [4,10,11].
All studies with data from only high-income countries
were excluded. We double-reviewed the titles and abstracts
of the remaining citations. The full-text of included citations
was retrieved where possible and double-reviewed for inclu-
sion with discrepancies resolved by consensus between
reviewers. We excluded animal, in-vitro and immunogeni-
city studies, those without primary data on outcomes of
interest, time-series observational studies with only post-
vaccine introduction data, and studies conducted among
vulnerable populations not representative of the general
population. We included randomized controlled trials
(RCTs), cohort and observational studies (case-control and
pre- vs. post-vaccine introduction time periods) that
assessed use of Hib or PCV vaccines and the effect on Hib
or PCV-specific meningitis, bacterial or probable bacterial
meningitis according to authors’ case definition (typically,
according to WHO criteria on CSF findings [12]), or
all-cause meningitis incidence or mortality or all-cause
mortality among children less than five years of age in low-
or middle-income countries, if the study design included a
control group (or time period in the instance of pre- vs.
post vaccine introduction time-series studies) and standard
error information was available. For studies evaluating the
effectiveness of PCVs, we also abstracted vaccine serotype-
specific (VT) and all-serotype (AT) outcomes. Foreign
language articles were reviewed by proficient abstractors or
translated where possible. In instances where the same out-
come was reported from multiple citations studying the
same or overlapping study populations, we selected only the
publication with the most complete or recent results for
inclusion.
We double-abstracted information about the study
location, design, population characteristics and size, type
of vaccine, and immunization coverage directly into a
customized Microsoft Access database (Microsoft). All
included studies were independently abstracted and har-
monized by consensus, then re- confirmed by a senior
adjudicator. For outcomes of interest we abstracted
information on the number of events in the control (or
pre-introduction) and intervention (or post-introduc-
tion) groups, effect measures (risk ratios, RR) and stan-
dard error information by numbers of doses of vaccine
administered. All effect estimates were converted into
RR where otherwise presented and 95% confidence
intervals calculated from available information in the
publication and population data from national [13] and
United Nations [14] statistical sources when necessary.
For pre- vs. post-vaccine introduction time-series stu-
dies, the effect measure was typically calculated by com-
paring number of events occurring in the last year prior
to vaccine introduction (pre-introduction) to number of
events in the last year for which data are available post-
vaccine introduction (post-introduction). When available,
immunization coverage data informed categorization of
years into these time periods. Results were sometimes
available from the same setting for both pre- vs. post-
introduction and nested case-control study designs, and
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in these instances the case-control data were used in the
analysis. For RCTs, age of the study population indicates
age at time of enrollment recruitment.
Quality assessment and effect size estimates for LiST
We assessed the generalizability and quality of evidence
using the CHERG scoring system [8]; the Cochrane Colla-
boration’s GRADE criteria [15] for determining risk of
bias were used to guide score assignment for RCTs; and
the Newcastle-Ottawa Quality Assessment Scale [16] was
used to inform quality assessment for non-randomized
studies in meta-analyses. Due to the severity of meningitis,
in which virtually all diagnosed cases are hospitalized,
population generalizability was not downgraded for studies
ascertaining only hospitalized cases. Details of study data
quality scoring, including inclusion in relevant Cochrane
reviews [10,11] are presented in Supplementary Tables 1
and 2 in Additional File 1.
We log-transformed study effect measures (RR), strati-
fied analyses by study design (RCT, case-control, pre-
post-introduction) and number of vaccine doses for out-
comes, and pooled estimates with more than one study
Figure 1 PubMed literature search terms
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available in a stratum. Meta-analysis of effect measures
was conducted using the DerSimonian-Laird pooled risk
ratio to provide conservative estimates in the presence
of heterogeneity and presented with a 95% confidence
interval (CI). All analyses were performed using STATA
software (version 12.1, Stat Corp, College Station, TX).
Sensitivity analyses included pooling studies with exact
number and greater number of doses (i.e. combined
effects of 1 dose with those of ≥ 1 doses), restricted age
groups, multi-year post-introduction time periods
(rather than single years), and apparent elimination (i.e.
zero events) in the post-introduction time period in
time-series studies.
LiST projects the impact of child survival interven-
tions on syndrome-specific causes of child mortality. To
provide an effect size estimate for inclusion in LiST, we
pooled estimates across multiple studies (≥2) of the
same design reporting dose-specific effects for outcomes
approximating meningitis mortality, then combined
these with meningitis etiology data from existing reviews
[17,18] to determine the Hib and PCV vaccine preventa-
ble fractions of childhood meningitis mortality. We
computed 1,000 Monte Carlo simulations for each para-
meter given a triangular distribution and uncertainty
limits determined by the 95% uncertainty interval for
each of the parameters (i.e. proportion of meningitis
caused by Hib or PCV, vaccine effectiveness and for
PCV the vaccine serotype coverage.) Multiplying these
simulated parameters and using the resulting distribu-
tion of vaccine attributable fractions, we took the 2.5th
and 97.5th percentile as the approximate central 95%
uncertainty interval. The estimated values for meningitis
etiology, vaccine serotype coverage and vaccine preven-
table fractions of childhood meningitis mortality are for
illustrative purposes and can be modified by LiST users.
Results
Studies identified
The systematic literature review yielded 3599 unique
citations from Pubmed and 1267 non-deduplicated cita-
tions from other sources (Figure 2), of which 20 con-
tained abstractable data on the effects of Hib conjugate
vaccines (n=18) and PCVs (n=2) in prevention of
meningitis outcomes or all-cause mortality in low- and
middle-income countries. Eligible citations were fre-
quently excluded in full-text screening due to reporting
of overlapping data with another citation, lack of a
clearly-defined population for catchment area, or failure
to meet analytic criteria due to lack of standard error
information [19-45].
Quality assessment and Hib vaccine effects
The 18 included studies reported the effects of Hib-
containing conjugate vaccines including PRP-tetanus
toxoid (PRP-T) or PRP-diphtheria toxoid (PRP-CRM),
alone or mixed with other antigens. Characteristics and
outcomes from included studies are summarized in
additional file, Table 3. Note that this table is in the
additional file as it was too large to present in the docu-
ment. Our primary objective was to estimate the effects
of Hib conjugate vaccines on childhood meningitis mor-
tality; we identified a single RCT [46] from Indonesia
reporting the effects on all-cause meningitis mortality
(RR: 0.87, 95% CI: 0.32-2.41), but it cannot be included
in LiST as CHERG guidelines require ≥2 studies for an
effect. Similarly, a single RCT [46] (RR: 0.11, 95% CI:
0.01-1.17) and a very-low-quality case-control study [47]
(RR: 0.29, 95% CI: 0.06-1.37) reported non-statistically
significant reductions in risk of Hib meningitis mortal-
ity. Also, evidence on the effect of at least one dose of
Hib conjugate vaccine on all-cause mortality was avail-
able from RCTs in Indonesia [48] and The Gambia [46],
yielding a pooled estimate of a 4% reduction in all-cause
mortality (RR: 0.96, 95% CI: 0.86-1.08), but since LiST
models syndrome-specific intervention effects, this out-
come is not recommended for the effect estimate.
More evidence of the effects of Hib conjugate vaccines
was available for meningitis morbidity outcomes. Observa-
tional studies of the effects of Hib conjugate vaccines on
meningitis outcomes included case-control studies of Hib
vaccine effectiveness (n=6) and time-series analyses com-
paring outcomes pre- and post-Hib vaccine introduction
often using surveillance data (n=9). A majority of the case-
control studies were from African countries (n=4) while
most time-series analyses were conducted in Latin America
and Caribbean countries (n=7). The evidence of the effects
of Hib on meningitis outcomes was limited in the Asia
(1 RCT, 1 case-control study) and Oceania (1 time-series
analysis) regions. Three studies, including a single RCT
[48] (RR=0.50, 95% CI: 0.27-0.82) and two pre-post vaccine
introduction time-series analyses [49,50] (RR=0.70, 95% CI:
0.54-0.89) estimated the overall effect of Hib conjugate vac-
cine on incidence of all-cause meningitis. A single RCT
[48] and six observational studies (case-control and time-
series analyses) [49-54] provided very-low-to-moderate
quality evidence on the effect of Hib vaccine on incidence
of acute bacterial or probable bacterial meningitis.
Thus, although our primary interest was to estimate
dose-specific effects of Hib conjugate vaccine on menin-
gitis mortality, sufficient evidence was available only for
Hib meningitis morbidity outcomes. Thirteen of the
observational studies reporting morbidity outcomes
[49-61], of very-low-to-moderate quality, estimated
effects on Hib meningitis incidence, but dose-specific
effects were only available from the subset that were
case-control studies (Figure 3). Our meta-analysis of the
four pooled case-control studies examined the dose-
specific effect of Hib conjugate vaccines on Hib meningitis
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morbidity (1 dose: RR=0.64, 95% CI 0.38-1.06; 2 doses:
RR=0.09, 95% CI 0.03-0.27; 3 doses: RR=0.06, 95% CI
0.02-0.22); and these estimates were consistent with results
from three doses of Hib vaccine administered in two RCTs
[46,48] (pooled RR: 0.12, 95% CI: 0.03-0.51) and the
pooled estimate across time-series studies evaluating pre-
vs. post-Hib introduction (RR: 0.02; 95% CI: 0.00-0.15).
Quality assessment and PCV vaccine effects
We identified only two studies, both high-quality RCTs
among children age 1-30 months from South Africa [62]
and The Gambia [63], reporting the effects of PCV on
meningitis-related outcomes. The overall reduction in
all-cause mortality associated with at least one dose of
the nine-valent vaccine (PCV-9) was 10% across studies.
(pooled RR=0.90, 95% CI: 0.80-1.01), but as above, all-
cause mortality cannot be used for LiST. An estimate of
all-cause meningitis mortality reduction with three
doses of PCV-9 was only available from the South Afri-
can RCT (RR: 0.87, 95% CI: 0.32-2.41). Finally, both
RCTs also reported evidence on the effects of three
doses of PCV-9 on pneumococcal meningitis morbidity.
Although the findings indicate non-statistically signifi-
cant reductions in incidence of AT pneumococcal
Figure 2 Flow chart of studies reporting the effect of Hib or pneumococcal conjugate vaccines on meningitis outcomes.
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meningitis (pooled RR=0.88, 95% CI: 0.47-1.62) and to
VT meningitis in particular (pooled RR=0.16, 95% CI:
0.02-1.20), the direction and magnitude of the effects
were similar across both RCTs (Table 1, Figure 4).
Effect size estimates for inclusion in LiST
Using the CHERG grading system to provide recom-
mendations on evidence to be used to estimate the
effect sizes for inclusion in LiST, we only found
Figure 3 Meta-analysis of observational studies examining the effect of Hib conjugate vaccines on Hib meningitis incidence by: A) 1 dose, B) 2
doses, C) 3 doses of vaccine.
Davis et al. BMC Public Health 2013, 13(Suppl 3):S21
http://www.biomedcentral.com/1471-2458/13/S3/S21
Page 6 of 13
Table 1 Studies of the effect of pneumococcal conjugates vaccines with meningitis outcomes.
Quality Assessment Directness Effect
No of
studies
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sufficient data to estimate dose-specific effects of Hib
conjugate vaccines for the Hib meningitis morbidity out-
come. For Hib conjugate vaccines, evidence reported for
the effect on all-cause mortality, all-cause meningitis
mortality, all-cause and acute bacterial meningitis mor-
bidity were available from single or multiple studies of
varying study designs and different numbers of doses (e.
g. at least 1 dose or 3 doses) but dose-specific evidence
was only available for each dose (1, 2, and 3 doses sepa-
rately) from case-control observational studies evaluat-
ing the effects on Hib meningitis incidence.
Ideally, dose-specific effects should be estimated using
the same studies for each dose number, to reduce the
probability that the differential impact observed between
doses is due to inclusion of different studies rather than
actual differences between doses. We identified four case-
control studies reporting the dose-specific effects of Hib
conjugate vaccine on incidence of Hib meningitis, per-
formed sensitivity analyses including evidence from other
studies for which all dose-specific effects were not available,
and retained these other studies in the pooled estimates if
inclusion resulted in little or no impact on the effect mea-
sure. This measure of the protective effect of Hib conjugate
vaccines on incidence of Hib meningitis was assumed to
approximate the effects on Hib meningitis mortality.
Since LiST models the effects of interventions on syn-
drome-specific child mortality, we then combined the
pooled effects on Hib meningitis with meningitis etiol-
ogy data (i.e. proportion of meningitis due to Hib) to
determine the preventable fraction of childhood menin-
gitis mortality for inclusion in LiST as seen in Table 2.
We used meningitis etiology data from an existing
CHERG review [64] for illustrative purposes; the value
can be re-calculated with other source data and entered
by the LiST user. These combined data provide an esti-
mated dose-specific effect of Hib conjugate vaccines on
childhood meningitis mortality in low-and middle-
income countries ranging from a 14%, 36% and 38%
reduction in a meningitis belt setting with 1, 2 and 3
doses, respectively, and 17%, 42% and 43% reduction
elsewhere.
With respect to PCVs, two high-quality RCTs reported
the effects of PCV-9 on both all-cause mortality and pneu-
mococcal meningitis in low-income countries. As above,
because LiST does not model the effect of childhood inter-
ventions on all-cause mortality, we used the pooled esti-
mate of the effects of 3 doses of PCV-9 against vaccine-
type pneumococcal meningitis, combined with meningitis
etiology data (proportion of meningitis due to pneumo-
coccus) and vaccine serotype coverage (proportion of
Figure 4 Meta-analysis of randomized controlled trials (RCTs) examining the effect of three doses of pneumococcal conjugate vaccine on
incidence of vaccine-type (VT) pneumococcal meningitis.
Davis et al. BMC Public Health 2013, 13(Suppl 3):S21
http://www.biomedcentral.com/1471-2458/13/S3/S21
Page 8 of 13
pneumococcal meningitis caused by vaccine serotypes
approximated from invasive pneumococcal disease) from
existing reviews [65,66] to provide an estimated effect of
PCV on childhood meningitis mortality in low-and mid-
dle-income countries. Applying this approach to an exam-
ple using the existing 10-valent PCV (PCV-10), we
estimated region-specific effects ranging from 28-35%
reduction in childhood meningitis mortality with 3 doses
of PCV-10 (Table 3). Use of the existing thirteen-valent
PCV (PCV-13) would likely increase the effect size.
Discussion
Lack of dose-specific estimates on the effects of Hib and
PCV on childhood meningitis mortality from high-quality
studies (e.g. RCTs) complicated the quantification of effect
sizes to be incorporated into LiST. Additionally, existing
CHERG guidelines are more easily applied to interventions
with a single coverage stratum (e.g. coverage with 3 doses
of vaccine) rather than dose-specific effects (e.g. coverage
with 1, 2 and 3 vaccine doses) which require evidence for
the effect of each dose across multiple studies.
Table 3 Effect size estimates of pneumococcal (SP) conjugate vaccines (PCV) on childhood meningitis mortality for
inclusion in LiST. (A) Approximated using evidence from existing reviews and can be edited by the LiST user [1]. (B)
Approximated from the proportion of invasive pneumococcal disease caused by vaccine serotypes in the existing 10-
valent PCV from an existing review and can be edited by the LiST user [17]. (C) Estimate of the effectiveness of PCV
against vaccine-serotype SP meningitis mortality (risk ratio) from this review. (D) Effect size for PCV on meningitis
mortality for LiST calculated by multiplying (A) x (B) x (C). (E) Uncertainty bounds.
Proportion of all-cause
meningitis mortality due to
SP [1,18]
(A)
Proportion of SP meningitis
caused by vaccine serotypes
(B)




Effect size for PCV on
meningitis mortality











0.52 (0.47-0.58) 0.72 (0.67-0.76) 0.84 (0.00-0.98) 0.32 0.05-0.34
Asia 0.52 (0.47-0.58) 0.70 (0.64-0.75) 0.84 (0.00-0.98) 0.31 0.05-0.33
Europe 0.52 (0.47-0.58) 0.81 (0.78-0.82) 0.84 (0.00-0.98) 0.35 0.06-0.38
Latin America
and Caribbean
0.52 (0.47-0.58) 0.77 (0.74-0.80) 0.84 (0.00-0.98) 0.34 0.06-0.36
Oceania 0.52 (0.47-0.58) 0.75 (0.63-0.84) 0.84 (0.00-0.98) 0.33 0.06-0.35
Table 2 Effect size estimates of Hib conjugate vaccines on childhood meningitis mortality for inclusion in LiST. (A)
Approximated using evidence from existing reviews and can be edited by the LiST user. (B) Estimate of the
effectiveness of Hib vaccines against Hib meningitis mortality (risk ratio) from this review. (C) Effect size for Hib
conjugate vaccines on meningitis mortality for LiST calculated by multiplying (A) x (B). (D) Uncertainty bounds.
†Effectiveness of Hib vaccines against Hib meningitis mortality is approximated by incidence of Hib meningitis
disease.
Proportion of all-cause meningitis
mortality due to Hib [1]
(A)
Effectiveness of Hib vaccines against Hib
meningitis mortality
(risk ratio)†(B)
Effect size for Hib vaccine on
meningitis mortality







0.40 (0.30-0.52) 0.36 (0.0-0.62) 0.14 0.03-0.20
2
doses
0.40 (0.30-0.52) 0.91 (0.73-0.97) 0.36 0.27-0.41
3
doses




0.46 (0.40-0.54) 0.36 (0.0-0.62) 0.17 0.03-0.22
2
doses
0.46 (0.40-0.54) 0.91 (0.73-0.97) 0.42 0.34-0.45
3
doses
0.46 (0.40-0.54) 0.94 (0.78-0.98) 0.43 0.36-0.46
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Despite the limited number of RCTs evaluating the
effects of Hib conjugate vaccine on childhood meningitis
mortality, we identified considerable evidence from
observational studies, both case-control and time-series
pre- and post-vaccine introduction, and across a range
of meningitis outcomes, with relative consistency
observed across study designs and settings. We also per-
formed a series of sensitivity analyses including studies
with restricted age ranges and different numbers of vac-
cine doses (e.g. effects of exactly 3 doses combined with
those of 3 or more doses), and the effect on incidence
of Hib meningitis appeared robust in sensitivity analyses.
For comparison, we assessed our findings with those
from two recent global reviews measuring the efficacy of
Hib vaccine against invasive Hib disease in a meta-analysis
of RCTs by Griffiths et al. [67], and a review of observa-
tional studies by Jackson et al.[68] Among studies from
developing countries [69] we included in our analyses the
same studies with the exception of those lacking either
clearly defined populations or sufficient information to
calculate standard error.31[70] Despite these slight differ-
ences in included studies, and in specificity of outcome of
interest, these two reviews reported pooled estimates of
Hib conjugate vaccine efficacy against invasive Hib disease
consistent with our estimates. We identified limited data
available for PCV from observational studies or other
reviews to allow for a similar assessment of the consis-
tency of our results, but this will be possible when PCV
impact assessments from early adopting low-income coun-
tries become available in the near future.
These estimates, as may be true of LiST estimates for
some other vaccines, probably significantly underesti-
mate the population-wide impact of the interventions.
The impact measures used for the LiST estimates pro-
vided here reflect the indirect or herd effect minimally if
at all (as they are based on case-control studies and
RCTs) and LiST does not currently incorporate indirect
effects into projections. However, its importance is well-
documented in empirical studies in developed countries
[71-76], and would be expected to be significant for
populations both within and beyond the age groups
modeled in LiST.
Several other limitations may affect these estimates as
well, including the quality and comparability of studies
in the analysis and the assumptions required to quantify
an effect size for inclusion in LiST. Higher-quality data
was available for some Hib outcomes but these either
were from single studies or did not provide dose-specific
effect estimates. While there was some data from most
regions, there was not sufficient data to provide region-
specific estimates of the effects of Hib or PCV vaccines
on meningitis. The generalizability of the two PCV stu-
dies, particularly for the South African trial limited to
hospitalized children, is not clear. Incomplete documen-
tation of vaccination status in case-control studies, and
of immunization coverage for time-series impact assess-
ments, could also have biased results. Indirect effects
may provide an important contribution to vaccine
impact, but no data were available for PCV and LiST
does not currently model the impact of indirect effects
of interventions. Future versions of LiST may be able to
incorporate estimates of both direct and indirect effects
of interventions.
In addition to the limitations of the vaccine efficacy or
effectiveness data, the assumptions and approximations
required to be able to quantify the dose-specific effects of
Hib and PCV vaccines provide additional uncertainty in
the results. First, we assumed that vaccine effects on inci-
dence of Hib meningitis and vaccine-type pneumococcal
meningitis approximate effects on organism-specific child-
hood meningitis mortality. Bacterial meningitis typically
causes severe disease and with a high case fatality ratio,
therefore this assumption is plausible. Second, we used
meningitis etiology data from an existing review [77] to
estimate the proportion of meningitis due to Hib or pneu-
mococcus. Third, for PCV, we assumed that vaccine cov-
erage of serotypes causing invasive pneumococcal disease
from a recent review [78] was equivalent to coverage of
serotypes causing pneumococcal meningitis mortality; this
may not be completely accurate, since most IPD cases are
due to bacteremic pneumonia, and syndrome-specific ser-
otype differences between syndromes have been reported
[79]. The assumed values of vaccine-preventable fractions
of childhood meningitis mortality were for illustrative pur-
poses using available evidence, and can be changed by the
LiST user if higher-quality or more representative data are
available for individual country projections. The multipli-
cation of multiple parameters to estimate the vaccine-
preventable fraction of meningitis mortality increases the
degree of uncertainty. However, we are encouraged by the
consistency of our findings with results from single RCTs
and observational studies from other similar reviews. The
results of this analysis suggest that 3 doses of Hib and
PCV together would prevent approximately three-quarters
of childhood meningitis mortality, leaving a remaining
one-quarter caused by non-vaccine type pneumococcal
meningitis, meningococcal meningitis and other causes of
meningitis/encephalitis.
Conclusions
Estimates of the dose-specific effectiveness of PCVs and
Hib conjugate vaccines in preventing childhood menin-
gitis mortality are limited by sparse data that met the
criteria for our meta-analysis, including high quality
prospective studies in low income settings. Despite these
limitations, available evidence on impact of these
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vaccines on meningitis morbidity indicates that a major-
ity of childhood meningitis mortality is preventable with
existing Hib and PCV vaccines, and these findings are
consistent with other empirical evidence and reviews.
Our understanding of the impact of PCV in low-income
settings is likely to significantly improve over the next
several years as results from early PCV adopting coun-
tries are made publicly available. Inclusion of dose-
specific and indirect effects of interventions will likely
improve the accuracy of LiST country impact projections.
Key messages
Available evidence indicates that a majority of childhood
meningitis mortality is preventable with existing Hib
and PCV vaccines and these findings are consistent with
other empirical evidence and reviews. This review quan-
tified the effects of Hib and pneumococcal conjugate
vaccines and will be incorporated into the Lives Saved
Tool (LiST) to model the projected impact on childhood
meningitis mortality in low income countries.
Additional material
Additional File 1: Supplementary Tables 1,2 and 3. Supplementary
Table 1 (sheet 1): Complete data on included Hib studies. Supplementary
Table 2 (sheet 2): Compete data on included PCV studies. Supplemental
Table 3: Data from final Hib studies used in effect size estimation.
List of abbreviations used
AT: all-seroypes of pneumococcus; CHERG: Child Health Epidemiology
Reference Group; CI: confidence interval; Hib: Haemophilus influenzae type b;
LiST: Lives Saved Tool; PCV: pneumococcal conjugate vaccine; RCT:





SD supervised the abstraction and drafted and edited the manuscript. DF
edited the manuscript. HJ conceived of the study, performed all analyses,
and edited the manuscript. All authors read and approved the final
manuscript.
Acknowledgements
We gratefully acknowledge Minjung Cho, Jonathan Mosser, Sonia Hegde,
Ashwini Gundawar, and Alan de Lima Pereira for their work in the screening
and abstraction of data for this manuscript, Lori Rosman for conducting the
literature search, and Jamie Perin for assistance in determining methods for
uncertainty analyses.
Declarations
The publication costs for this supplement were funded by a grant from the Bill &
Melinda Gates Foundation to the US Fund for UNICEF (grant 43386 to “Promote
evidence-based decision making in designing maternal, neonatal, and child health
interventions in low- and middle-income countries”). The Supplement Editor is the
principal investigator and lead in the development of the Lives Saved Tool (LiST),
supported by grant 43386. He declares that he has no competing interests.
This article has been published as part of BMC Public Health Volume 13
Supplement 3, 2013: The Lives Saved Tool in 2013: new capabilities and
applications. The full contents of the supplement are available online at
http://www.biomedcentral.com/bmcpublichealth/supplements/13/S3.
Funding
This work was supported by a grant from the Bill and Melinda Gates
Foundation to the US Fund for UNICEF for the ongoing work of the Child
Health Epidemiology Reference Group (CHERG).
Published: 17 September 2013
References
1. Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE, Rudan I,
Campbell H, Cibulskis R, Li M, Mathers C, Black RE, Child Health
Epidemiology Reference Group of WHO and UNICEF: Global, regional, and
national causes of child mortality: an updated systematic analysis for
2010 with time trends since 2000. Lancet 2012, 379(9832):2151-61, doi:
10.1016/S0140-6736(12)60560-1. Epub 2012 May 11.
2. Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I: Global
and regional risk of disabling sequelae from bacterial meningitis: a
systematic review and meta-analysis. Lancet Infect Dis 2010, 10(5):317-28,
doi: 10.1016/S1473-3099(10)70048-7.
3. Watt J, Wolfson L, O’brien K, Henkle W, Deloria-Knoll M, McCall N, Lee E,
Levine O, Hajjeh R, et al: Burden of disease caused by Haemophilus
influenzae type B in children younger than 5 years: global estimates.
Lancet 2009, 374:903-911.
4. O’Brien KL, Wolfson L, Watt J, Henkle E, Deloria-Knoll M, McCall N, et al:
Burden of disease caused by Streptococcus pneumonia in children
younger than 5 years: global estimates. Lancet 2009, 374:893-902.
5. Country introductions of new and underused vaccines. New and
Underused Vaccine Support GAVI Alliance;, Accessed online January 26, 2013,
at http://www.gavialliance.org/results/goal-level-indicators/vaccine-goal-
indicators/.
6. Vaccine Information Management System (VIMS) Report: Global Vaccine
Introduction. International Vaccine Access Center, Johns Hopkins School of
Public Health;, Accessed Dec. 14, 2012 at http://www.jhsph.edu/research/
centers-and-institutes/ivac/vims/IVAC-VIMS-Report-2012-12.pdf.
7. LiST: The Lives Saved Tool: An evidence-based tool for estimating
intervention impact. Johns Hopkins University; 2013, Accessed online Jan.
27, 2013 at http://www.jhsph.edu/departments/international-health/centers-
and-institutes/institute-for-international-programs/list/.
8. Walker N, Fischer-Walker C, Bryce J, Bahl J, Cousens S: Standards for CHERG
reviews of intervention effects on child survival. International Journal of
Epidemiology 2010, 39:i21-i31.
9. World Bank: World Bank List of Economies, December 2010., Latest
version available online at http://siteresources.worldbank.org/
DATASTATISTICS/Resources/CLASS.XLS.
10. Lucero MG, Dulalia VE, Nillos LT, Williams G, Parreño RAN, Nohynek H,
Riley ID, Makela H: Pneumococcal conjugate vaccines for preventing
vaccine-type invasive pneumococcal disease and X-ray defined
pneumonia in children less than two years of age (Review). The Cochrane
Library 2009, 4.
11. Swingler GH, Michaels D, Hussey GGD: Conjugate vaccines for preventing
Haemophilus influenza type B infections (Review). The Cochrane Library
2009, 3, (Withdrawn).
12. Vaccine Assessment and Monitoring Team, Department of Vaccines and
Biologicals: WHO-recommended standards for surveillance of selected
vaccine-preventable diseases. Geneva: World Health Organization; 2003,
WHO/V&B/03.01 Accessed Dec. 11, 2012 at http://whqlibdoc.who.int/hq/
2003/WHO_V&B_03.01.pdf.
13. Oficina National de Estadisticas de Cuba: Poblacion año Calendario y
Edades Simples 1990-2020., Accessed online Dec. 14, 2012 at http://www.
one.cu/EstadisticaPoblacion/EstadisticaPoblacion.asp.
14. United Nations Statistics Division: United Nations Demographic
Yearbooks., Accessed December 14. 2012 at http://unstats.un.org/unsd/
demographic/products/dyb/dyb2.htm.
15. Cochrane Handbook for Systematic Reviews of Interventions Version
5.1.0 [updated March 2011]. The Cochrane Collaboration;Higgins JPT,
Green S 2011:, Available from http://handbook.cochrane.org/.
16. Wells G, Shea B, O’connell D, Peterson J, Welch V, Losos M, Tugwell P: The
Newcastle-Ottawa Scale (NOS) for assessing the quality of
Davis et al. BMC Public Health 2013, 13(Suppl 3):S21
http://www.biomedcentral.com/1471-2458/13/S3/S21
Page 11 of 13
nonrandomized studies in meta-analysis. 2010, Accessed January 26, 2007
at http://www.ohri.ca/programs/clinical_epidemiology/oxford_web.ppt.
17. Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE, Rudan I,
Campbell H, Cibulskis R, Li M, Mathers C, Black RE, Child Health
Epidemiology Reference Group of WHO and UNICEF: Global, regional, and
national causes of child mortality: an updated systematic analysis for
2010 with time trends since 2000. Lancet 2012, 379(9832):2151-61, doi:
10.1016/S0140-6736(12)60560-1. Epub 2012 May 11.
18. Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Freimanis Hance L,
Reithinger R, Muenz LR, O’Brien KL: Systematic evaluation of serotypes
causing invasive pneumococcal disease among children under five: the
pneumococcal global serotype project. PLoS Med 2010, 7(10):pii:
e1000348.
19. von Gottberg A, Madhi SA, Quan V, Soma K, Huebner R, Flannery B,
Schuchat A, Klugman KP, Group for Enteric, Respiratory and Meningeal
Disease Surveillance in South Africa (Germ-SA): Impact of conjugate
Haemophilus influenzae type b (Hib) vaccine introduction in South
Africa. Pediatr Infect Dis J 2004, 23(9):842-847.
20. Abate H, Falaschi A, Garcia B: Enfermedad invasiva por Haemophilus
influenzae b: disminucion de la incidencia en la era postvaccinal. Arch
Argent Pediatr 2003, 101(1):26-30.
21. Adegbola RA, Usen SO, Weber M, Lloyd-Evans N, Jobe K, Mulholland K,
McAdam KPWJ, Greenwood BM, Milligan PJM: Haemophilus influenzae
type b meningitis in The Gambia after introduction of a conjugate
vaccine. Lancet 1999, 354(9184):1091-1092.
22. Agudelo CI, Muñoz N, De la Hoz F: Rapid assessment of the impact of
Haemophilus influenzae vaccine serotype b in Colombia. Rev Panam
Salud Publica 2000, 8(3):181-184.
23. Almeida A, de Filippis I, de Abreu AO, Ferreira DG, Gemal AL, Marzochi KBF:
Occurrence of Haemophilus influenzae strains in three Brazilian states
since the introduction of a conjugate Haemophilus influenzae type b
vaccine. Brazilian Journal of Medical and Biological Research 2005,
38(5):777-781.
24. Caro-Cassali M, Vargas-Campos A, Mohs-Villalta E, Arguedas-Mohs A:
Invasive type B Haemophilus influenzae infections at the National
Children’s Hospital one year after the introduction of the conjugated
vaccine. Bol Med Hosp Inf Mex 1995, 52(7):426-430.
25. Cisse MF, Breugelmans JG, BÄ M, Diop MB, Faye PC, Mhlanga B, Mueller JE,
Koffi D, Gessner BD: The elimination of haemophilus influenzae type b
meningitis following conjugate vaccine introduction in Senegal. Pediatric
Infectious Disease Journal 2010, 29(6):499-503.
26. Cowgill KD, Ndiritu M, Nyiro J, Slack MPE, Chiphatsi S, Ismail A, Kamau T,
Mwangi I, English M, Newton CRJC, et al: Effectiveness of Haemophilus
influenzae Type b Conjugate Vaccine Introduction Into Routine
Childhood Immunization in Kenya. Journal of the American Medical
Association 2006, 296(6):671-678.
27. Diaz JM, Catalan L, Urrutia MT, Prado V, Ledermann W, Mendoza C,
Topelberg S: Trends of etiology of acute bacterial meningitis in Chilean
children from 1989 to 1998: impact of the anti-H influenzae type b
vaccine. Revista medica de Chile 2001, 129(7):719-726.
28. Dickinson FO, Perez AE, Galindo MA, Quintana I: [Impact of vaccination
against Haemophilus influenzae type b in Cuba]. Rev Panam Salud
Publica 2001, 10(3):169-173.
29. Freitas HS, Merchan-Hamann E: [Impact of anti-Hib conjugate vaccine on
the incidence of Haemophilus influenzae meningitis in Brazil’s Federal
District: Results of a three-year follow-up]. Revista Panamericana de Salud
Publica 2006, 19(1):33-37.
30. Dickinson FO, Pérez AE: Bacterial meningitis in children and adolescents:
an observational study based on the national surveillance system. BMC
Infect Dis 2005, 5:103.
31. Lee HJE, Lewis RF, Makumbi I, Kekitiinwa A, Ediamu TD, Bazibu M, Braka F,
Flannery B, Zuber PL, Feikin DR: Haemophilus influenzae type b conjugate
vaccine is highly effective in the Ugandan routine immunization
program: a case-control study. Tropical Medicine and International Health
2008, 13(4):495-502.
32. Madhi SA, Petersen K, Khoosal M, Huebner RE, Mbelle N, Mothupi R,
Saloojee H, Crewe-Brown H, Klugman KP: Reduced effectiveness of
Haemophilus influenzae type b conjugate vaccine in children with a
high prevalence of human immunodeficiency virus type 1 infection. The
Pediatric infectious disease journal 2002, 21(4):315-321.
33. Martin M, Casellas JM, Madhi SA, Urquhart TJ, Delport SD, Ferrero F,
Chamany S, Dayan GH, Rose CE, Levine OS, et al: Impact of haemophilus
influenzae type b conjugate vaccine in South Africa and Argentina.
Pediatr Infect Dis J 2004, 23(9):842-847.
34. McCormick DW, Molyneaux E: Bacterial Meningitis and Haemophilus
influenzae Type b Conjugate Vaccine, Malawi. Emerg Infect Dis 2011,
17(4):688-690.
35. Miranzi SS, de Moraes SA, de Freitas IC: Impact of the Haemophilus
influenzae type b vaccination program on HIB meningitis in Brazil.
Cadernos de saude publica Ministrio da Saude, Fundao Oswaldo Cruz, Escola
Nacional de Saude Publica 2007, 23(7):1689-1695.
36. Montano Lotito AA, Algorta Rusinol MG, Pirez Garcia MC, Pascale Mello A,
Farcilli Ruiz RI, Ferrari Chiesa AM: Enfermedades invasivas por
Haemophilus influenzae tipo b. Impacto de la vacunacion en los ninos
que ingresan al Centro Hospitalario Pereira Rossell. Rev Med Urug 2001,
17(3):166-170.
37. Muganga N, Uwimana J, Fidele N, Gahimbare L, Gessner BD, Mueller JE,
Mhlanga BR, Katsande R, Herbinger K-H, Rugambwa C: Haemophilus
influenzae type b conjugate vaccine impact against purulent meningitis
in Rwanda. Vaccine 2007, 25:7001-7005.
38. Nascimento-Carvalho CM, Moreno-Carvalho OA: [Etiology of bacterial
meningitis in a cohort from Salvador, Bahia]. Arq Neuropsiquiatr 1998,
56(1):83-87.
39. Nascimento-Carvalho CM, Moreno-Carvalho OA: Etiology of bacterial
meningitis among children aged 2-59 months in Salvador, Northeast
Brazil, before and after routine use of Haemophilus influenzae type B
vaccine. Arq Neuropsiquiatr 2004, 62(2):250-252.
40. Pérez AE, Dickinson FO, Rodríguez M: Community acquired bacterial
meningitis in Cuba: a follow up of a decade. BMC Infect Dis 2010, 10:130.
41. Renner LA, Newman MJ, Ahadzie L, Antwi-Agyei KO, Eshetu M:
Introduction of Haemophilus influenzae type B conjugate vaccine into
routine immunization in Ghana and its impact on bacterial meningitis in
children younger than five years. The Pediatric infectious disease journal
2007, 26(4):356-358.
42. Ribeiro GS, Reis JN, Cordeiro SM, Lima JB, Gouveia EL, Petersen M,
Salgado K, Silva HR, Zanella RC, Almeida SC, et al: Prevention of
Haemophilus influenzae type b (Hib) meningitis and emergence of
serotype replacement with type a strains after introduction of Hib
immunization in Brazil. J Infect Dis 2003, 187(1):109-116.
43. Takemura NS, Andrade SM: Haemophilus influenzae type b meningitis in
the state of Paraná, Brazil. J Pediatr (Rio J) 2001, 77(5):387-392.
44. Verghese VP, Friberg IK, Cherian T, Raghupathy P, Balaji V, Lalitha MK,
Thomas K, John TJ, Steinhoff MC: Community effect of haemophilus
influenzae type b vaccination in India. Pediatric Infectious Disease Journal
2009, 28(8):738-740.
45. von Gottberg A, de Gouveia L, Madhi SA, du Plessis M, Quan V, Soma K,
Huebner R, Flannery B, Schuchat A, Klugman K: Impact of conjugate
Haemophilus influenzae type b (Hib) vaccine introduction in South
Africa. Bull World Health Organ 2006, 84(10):811-8.
46. Mulholland K, Hilton S, Adegbola R, Usen S, Oparaugo A, Omosigho C,
Weber M, Palmer A, Schneider G, Jobe K, et al: Randomised trial of
Haemophilus influenzae type-b tetanus protein conjugate for prevention
of pneumonia and meningitis in Gambian infants. Lancet 1997,
349(9060):1191-1197.
47. Fleming JA, Dieye Y, Ba O, Mutombo wa Mutombo B, Diallo N, Faye PC,
Ba M, Cisse MF, Diallo AG, Slack MPE, et al: Effectiveness of Haemophilus
influenzae type b conjugate vaccine for prevention of meningitis in
Senegal. The Pediatric infectious disease journal 2011, 30(5):430-2.
48. Gessner BD, Sutanto A, Linehan M, Gede Djelantik IG, Fletcher T,
Gerudug IK, Ingerani , Mercer D, Moniaga V, Moulton LH, et al: Incidences
of vaccine-preventable Haemophilus influenzae type b pneumonia and
meningitis in Indonesian children: hamlet-randomised vaccine-probe
trial. Lancet (British edition) 2005, 365(9453):43-52.
49. Russell FM, Fakakovi T, Paasi S, Ika A, Mulholland EK: Reduction of
meningitis and impact on under-5 pneumonia after introducing the Hib
vaccine in the Kingdom of Tonga. Ann Trop Paediatr 2009, 29(2):111-117.
50. Wilson N, Mansoor O, Wenger J, Martin R, Zanardi L, O’Leary M,
Rabukawaqa V: Estimating the Haemophilus influenzae type b (Hib)
disease burden and the impact of Hib vaccine in Fiji. Vaccine 2003,
21(17-18):1907-1912.
Davis et al. BMC Public Health 2013, 13(Suppl 3):S21
http://www.biomedcentral.com/1471-2458/13/S3/S21
Page 12 of 13
51. Lewis RE, K A, Gessner BD, et al: Action for child survival: elimination of
Haemophilus influenzae type b meningitis in Uganda. Bull World Health
Organ 2008, 86:292-301.
52. Baqui AH, ElArifeen S, Saha SK, Persson L, Zaman K, Gessner BD,
Moulton LH, Black RE, Santosham M: Effectiveness of Haemophilus
influenzae type b conjugate vaccine on prevention of pneumonia and
meningitis in Bangladeshi children: a case-control study. Pediatric
Infectious Disease Journal 2007, 26(7):565-571.
53. Dickinson Meneses FlO, Perez Rodriguez AE: Las meningoencefalitis
bacterianas en la poblacion infantil cubana: 1998-2000. Revcubapediatr
2002, 74(2):106-114.
54. Simoes LL, Andrade AL, Laval CA, Oliveira RM, Silva SA, Martelli CM,
Alves SL, Almeida RM, Andrade JG: [Impact of Haemophilus influenzae b
(Hib) vaccination on meningitis in Central Brazil]. Revista de saude publica
2004, 38(5):664-670.
55. Adegbola RA, Secka O, Lahai G, Lloyd-Evans N, Njie A, Usen S, Oluwalana C,
Obaro S, Weber M, Corrah T, et al: Elimination of Haemophilus influenzae
type b (Hib) disease from The Gambia after the introduction of routine
immunisation with a Hib conjugate vaccine: A prospective study. Lancet
2005, 366(9480):144-150.
56. Daza P, Banda R, Misoya K, Katsulukuta A, Gessner BD, Katsande R,
Mhlanga BR, Mueller JE, Nelson CB, Phiri A, et al: The impact of routine
infant immunization with Haemophilus influenzae type b conjugate
vaccine in Malawi, a country with high human immunodeficiency virus
prevalence. Vaccine 2006, 24(37-39):6232-6239.
57. Lee EH, Corcino M, Moore A, Garib Z, PeÃ±a C, SÃ¡nchez J, FernÃ¡ndez J,
Feris-Iglesias JsM, Flannery B: Impact of Haemophilus influenzae type b
conjugate vaccine on bacterial meningitis in the Dominican Republic
Impacto de la vacuna conjugada contra Haemophilus influenzae tipo b
sobre la meningitis bacteriana en la RepÃºblica Dominicana. Revista
Panamericana De Salud Publica-Pan American Journal of Public Health 2008,
24(3):161-168.
58. Kmetzsch CI, Schermann MT, Santana JC, Estima CL, Faraco FJ, Silva CM,
Conceição R: Occurrence of Haemophylus influenzae B meningitis after
the implementation of a mass vaccination program. J Pediatr (Rio J) 2003,
79(6):530-6.
59. Lagos R, Horwitz I, Toro J, San Martin O, Abrego P, Bustamante C,
Wasserman SS, Levine OS, Levine MM: Large scale, postlicensure, selective
vaccination of Chilean infants with PRP-T conjugate vaccine: practicality
and effectiveness in preventing invasive Haemophilus influenzae type b
infections. The Pediatric infectious disease journal 1996, 15(3):216-222.
60. Ribeiro GS, Lima JBT, Reis JN, Gouveia EL, Cordeiro SM, Lobo TS,
Pinheiro RM, Ribeiro CT, Neves AB, Salgado K, et al: Haemophilus
influenzae meningitis 5 years after introduction of the Haemophilus
influenzae type b conjugate vaccine in Brazil. Vaccine 2007,
25(22):4420-4428.
61. Ruocco G, Curto S, Savio M, Laurani H, Frocht R: Vaccination against
Haemophilus influenzae type b in Uruguay: experience and impact. Rev
Panam Salud Publica 1999, 5(3):197-199.
62. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N,
Vaccine Trialists Group: A trial of a 9-valent pneumococcal conjugate
vaccine in children with and those without HIV infection. N Engl J Med
2003, 349(14):1341-1348.
63. Cutts FT, Zaman SMA, Enwere G, Jaffar S, Levine OS, Okoko JB,
Oluwalana C, Vaughan A, Obaro SK, Leach A, McAdam KP, Biney E, Saaka M,
Onwuchekwa U, Yallop F, et al: Efficacy of nine-valent pneumococcal
conjugate vaccine against pneumonia and invasive pneumococcal
disease inThe Gambia: randomised, double-blind, placebo-controlled
trial. Lancet 2005, 365:1139-46.
64. Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE, Rudan I,
Campbell H, Cibulskis R, Li M, Mathers C, Black RE, Child Health
Epidemiology Reference Group of WHO and UNICEF: Global, regional, and
national causes of child mortality: an updated systematic analysis for
2010 with time trends since 2000. Lancet 2012, 379(9832):2151-61, doi:
10.1016/S0140-6736(12)60560-1. Epub 2012 May 11.
65. Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE, Rudan I,
Campbell H, Cibulskis R, Li M, Mathers C, Black RE, Child Health
Epidemiology Reference Group of WHO and UNICEF: Global, regional, and
national causes of child mortality: an updated systematic analysis for
2010 with time trends since 2000. Lancet 2012, 379(9832):2151-61, doi:
10.1016/S0140-6736(12)60560-1. Epub 2012 May 11.
66. Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Freimanis Hance L,
Reithinger R, Muenz LR, O’Brien KL: Systematic evaluation of serotypes
causing invasive pneumococcal disease among children under five: the
pneumococcal global serotype project. PLoS Med 2010, 7(10):pii:
e1000348.
67. Griffiths UK, Clark A, Gessner B, Miners A, Sanderson C, Sedyaningsih ER,
Mulholland KE: Dose-specific efficacy of Haemophilus influenzae type b
conjugate vaccines: a systematic review and meta-analysis of controlled
clinical trials. Epidemiol Infect 2012, 140:1343-1355.
68. Jackson C, Mann A, Mangtani P, Fine P: Systematic review of
observational data on effectiveness of Haemophilus influenzae type b
(Hib) vaccines to allow optimization of vaccination schedules. London
School of Hygiene and Tropical Medicine; 2012, doi: 10.1016/j.
vaccine.2010.03.075. Epub 2010 Apr 14.
74. Hennessy TW, Singleton RJ, Bulkow LR, Bruden DL, Hurlburt DA, Parks D,
et al: Impact of heptavalent pneumococcal conjugate vaccine on
invasive disease, antimicrobial resistance and colonization in Alaska
Natives : progress towards elimination of a health disparity. Vaccine
2005, 23(48-49):5464-73.
75. Flannery B, Heffernan RT, Harrison LH, Ray SM, Reingold AL, Hadler J, et al:
Changes in invasive pneumococcal disease among HIV-infected adults
living in the era of childhood pneumococcal immunization. Ann Int Med
2006, 144(1):1-9.
76. Whitney C: “Decline in Invasive Disease after the introduction of protein-
polysaccharide conjugate vaccine.”. NEJM 2003, 348:1737-46.
77. Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE, Rudan I,
Campbell H, Cibulskis R, Li M, Mathers C, Black RE, Child Health
Epidemiology Reference Group of WHO and UNICEF: Global, regional, and
national causes of child mortality: an updated systematic analysis for
2010 with time trends since 2000. Lancet 2012, 379(9832):2151-61, doi:
10.1016/S0140-6736(12)60560-1. Epub 2012 May 11.
78. Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Freimanis Hance L,
Reithinger R, Muenz LR, O’Brien KL: Systematic evaluation of serotypes
causing invasive pneumococcal disease among children under five: the
pneumococcal global serotype project. PLoS Med 2010, 7(10):pii:
e1000348.
79. Song JY, Nahm MH, Moseley MA: Clinical implications of pneumococcal
serotypes: invasive disease potential, clinical presentations, and
antibiotic resistance. J Korean Med Sci 2013, 28(1):4-15.
doi:10.1186/1471-2458-13-S3-S21
Cite this article as: Davis et al.: The effect of Haemophilus influenzae
type B and pneumococcal conjugate vaccines on childhood meningitis
mortality: a systematic review. BMC Public Health 2013 13(Suppl 3):S21.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Davis et al. BMC Public Health 2013, 13(Suppl 3):S21
http://www.biomedcentral.com/1471-2458/13/S3/S21
Page 13 of 13
